{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:27:45Z","timestamp":1790270865390,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T00:00:00Z","timestamp":1581465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T00:00:00Z","timestamp":1581465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Recent studies suggest that Src family kinase (SFK) plays important roles in systemic sclerosis and pulmonary fibrosis. However, how SFKs contributed to the pathogenesis of liver fibrosis remains largely unknown. Here, we investigated the role of Fyn, a member of SFK, in hepatic stellate cell (HSC) activation and liver fibrosis, and evaluated the anti-fibrotic effects of Saracatinib, a clinically proven safe Fyn inhibitor. Fyn activation was examined in human normal and fibrotic liver tissues. The roles of Fyn in HSC activation and liver fibrosis were evaluated in HSC cell lines by using Fyn siRNA and in Fyn knockout mice. The effects of Saracatinib on HSC activation and liver fibrosis were determined in primary HSCs and CCl\n                    <jats:sub>4<\/jats:sub>\n                    induced liver fibrosis model. We showed that the Fyn was activated in the liver of human fibrosis patients. TGF-\u03b2 induced the activation of Fyn in HSC cell lines. Knockdown of Fyn significantly blocked HSC activation, proliferation, and migration. Fyn deficient mice were resistant to CCl\n                    <jats:sub>4<\/jats:sub>\n                    induced liver fibrosis. Saracatinib treatment abolished the activation of Fyn, downregulated the Fyn\/FAK\/N-WASP signaling in HSCs, and subsequently prevented the activation of HSCs. Saracatinib treatment significantly reduced the severity liver fibrosis induced by CCl\n                    <jats:sub>4<\/jats:sub>\n                    in mice. In conclusions, our findings supported the critical role of Fyn in HSC activation and development of liver fibrosis. Fyn could serve as a promising drug target for liver fibrosis treatment. Fyn inhibitor Saracatinib significantly inhibited HSC activation and attenuated liver fibrosis in mouse model.\n                  <\/jats:p>","DOI":"10.1038\/s41419-020-2229-2","type":"journal-article","created":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T05:03:04Z","timestamp":1581483784000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Targeting Src family kinase member Fyn by Saracatinib attenuated liver fibrosis in vitro and in vivo"],"prefix":"10.1038","volume":"11","author":[{"given":"Guifang","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueke","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinke","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuihong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rifaat","family":"Safadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruizhao","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixian","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinying","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,12]]},"reference":[{"key":"2229_CR1","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1002\/hep.25670","volume":"56","author":"DY Zhang","year":"2012","unstructured":"Zhang, D. Y. & Friedman, S. L. Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology 56, 769\u2013775 (2012).","journal-title":"Hepatology"},{"issue":"1 Suppl","key":"2229_CR2","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/j.jhep.2015.02.039","volume":"62","author":"C Trautwein","year":"2015","unstructured":"Trautwein, C., Friedman, S. L., Schuppan, D. & Pinzani, M. Hepatic fibrosis: concept to treatment. J. Hepatol. 62 (1 Suppl.), S15\u2013S24 (2015).","journal-title":"J. Hepatol."},{"key":"2229_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1172\/JCI24282","volume":"115","author":"R Bataller","year":"2005","unstructured":"Bataller, R. & Brenner, D. A. Liver fibrosis. J. Clin. Invest. 115, 209\u2013218 (2005).","journal-title":"J. Clin. Invest"},{"key":"2229_CR4","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.bpg.2011.02.005","volume":"25","author":"UE Lee","year":"2011","unstructured":"Lee, U. E. & Friedman, S. L. Mechanisms of hepatic fibrogenesis. Best. Pr. Res Clin. Gastroenterol. 25, 195\u2013206 (2011).","journal-title":"Best. Pr. Res Clin. Gastroenterol."},{"key":"2229_CR5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1478-3231.2005.01192.x","volume":"26","author":"X Liu","year":"2006","unstructured":"Liu, X., Hu, H. & Yin, J. Q. Therapeutic strategies against TGF-beta signaling pathway in hepatic fibrosis. Liver Int. 26, 8\u201322 (2006).","journal-title":"Liver Int."},{"key":"2229_CR6","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1111\/febs.13665","volume":"283","author":"I Fabregat","year":"2016","unstructured":"Fabregat, I. et al. TGF-beta signalling and liver disease. FEBS J. 283, 2219\u20132232 (2016).","journal-title":"FEBS J."},{"key":"2229_CR7","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10555-016-9623-3","volume":"35","author":"RK Goel","year":"2016","unstructured":"Goel, R. K. & Lukong, K. E. Understanding the cellular roles of Fyn-related kinase (FRK): implications in cancer biology. Cancer Metastasis Rev. 35, 179\u2013199 (2016).","journal-title":"Cancer Metastasis Rev."},{"key":"2229_CR8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1124\/jpet.114.216044","volume":"351","author":"M Hu","year":"2014","unstructured":"Hu, M. et al. Therapeutic targeting of SRC kinase in myofibroblast differentiation and pulmonary fibrosis. J. Pharm. Exp. Ther. 351, 87\u201395 (2014).","journal-title":"J. Pharm. Exp. Ther."},{"key":"2229_CR9","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1002\/eji.201646876","volume":"47","author":"KA Ramirez-Valadez","year":"2017","unstructured":"Ramirez-Valadez, K. A., Vazquez-Victorio, G., Macias-Silva, M. & Gonzalez-Espinosa, C. Fyn kinase mediates cortical actin ring depolymerization required for mast cell migration in response to TGF-beta in mice. Eur. J. Immunol. 47, 1305\u20131316 (2017).","journal-title":"Eur. J. Immunol."},{"key":"2229_CR10","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.bbrc.2011.02.134","volume":"407","author":"AN Kim","year":"2011","unstructured":"Kim, A. N. et al. Fyn mediates transforming growth factor-beta1-induced down-regulation of E-cadherin in human A549 lung cancer cells. Biochem. Biophys. Res. Commun. 407, 181\u2013184 (2011).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2229_CR11","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1159\/000323996","volume":"26","author":"L Yu","year":"2010","unstructured":"Yu, L. et al. TGF-beta1 induces podocyte injury through Smad3-ERK-NF-kappaB pathway and Fyn-dependent TRPC6 phosphorylation. Cell Physiol. Biochem. 26, 869\u2013878 (2010).","journal-title":"Cell Physiol. Biochem"},{"key":"2229_CR12","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/ki.2015.293","volume":"89","author":"Y Yan","year":"2016","unstructured":"Yan, Y. et al. Src inhibition blocks renal interstitial fibroblast activation and ameliorates renal fibrosis. Kidney Int. 89, 68\u201381 (2016).","journal-title":"Kidney Int."},{"key":"2229_CR13","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/j.kint.2016.06.038","volume":"90","author":"HY Seo","year":"2016","unstructured":"Seo, H. Y. et al. Fyn deficiency attenuates renal fibrosis by inhibition of phospho-STAT3. Kidney Int. 90, 1285\u20131297 (2016).","journal-title":"Kidney Int"},{"key":"2229_CR14","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1002\/art.23436","volume":"58","author":"C Skhirtladze","year":"2008","unstructured":"Skhirtladze, C. et al. Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis. Arthritis Rheum. 58, 1475\u20131484 (2008).","journal-title":"Arthritis Rheum."},{"key":"2229_CR15","doi-asserted-by":"publisher","first-page":"6365","DOI":"10.1038\/onc.2008.250","volume":"27","author":"YM Chang","year":"2008","unstructured":"Chang, Y. M. et al. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530. Oncogene 27, 6365\u20136375 (2008).","journal-title":"Oncogene"},{"key":"2229_CR16","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/CAD.0b013e328325a867","volume":"20","author":"PN Lara Jr","year":"2009","unstructured":"Lara, P. N. Jr et al. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drugs 20, 179\u2013184 (2009).","journal-title":"Anticancer Drugs"},{"issue":"18 Suppl.","key":"2229_CR17","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1200\/jco.2007.25.18_suppl.3520","volume":"25","author":"J Tabernero","year":"2007","unstructured":"Tabernero, J. et al. Phase I study of AZD0530, an oral potent inhibitor of Src kinase: first demonstration of inhibition of Src activity in human cancers. J. Clin. Oncol. 25(18 Suppl.), 3520\u20133520 (2007).","journal-title":"J. Clin. Oncol."},{"key":"2229_CR18","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1136\/gut.2004.042127","volume":"54","author":"L Xu","year":"2005","unstructured":"Xu, L. et al. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut 54, 142\u2013151 (2005).","journal-title":"Gut"},{"key":"2229_CR19","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0022-2275(20)32030-7","volume":"41","author":"S Vogel","year":"2000","unstructured":"Vogel, S. et al. An immortalized rat liver stellate cell line (HSC-T6): a new cell model for the study of retinoid metabolism in vitro. J. Lipid Res. 41, 882\u2013893 (2000).","journal-title":"J. Lipid Res"},{"key":"2229_CR20","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.jhep.2016.11.004","volume":"66","author":"T Ramirez","year":"2017","unstructured":"Ramirez, T. et al. Aging aggravates alcoholic liver injury and fibrosis in mice by downregulating sirtuin 1 expression. J. Hepatol. 66, 601\u2013609 (2017).","journal-title":"J. Hepatol."},{"key":"2229_CR21","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1002\/hep.24190","volume":"53","author":"WI Jeong","year":"2011","unstructured":"Jeong, W. I. et al. Suppression of innate immunity (natural killer cell\/interferon-gamma) in the advanced stages of liver fibrosis in mice. Hepatology 53, 1342\u20131351 (2011).","journal-title":"Hepatology"},{"key":"2229_CR22","doi-asserted-by":"publisher","first-page":"L692","DOI":"10.1152\/ajplung.00390.2011","volume":"303","author":"GQ Cai","year":"2012","unstructured":"Cai, G. Q. et al. Neuronal Wiskott-Aldrich syndrome protein (N-WASP) is critical for formation of alpha-smooth muscle actin filaments during myofibroblast differentiation. Am. J. Physiol. Lung Cell Mol. Physiol. 303, L692\u2013L702 (2012).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"2229_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/srep08453","volume":"5","author":"P Che","year":"2015","unstructured":"Che, P. et al. S100A4 promotes pancreatic cancer progression through a dual signaling pathway mediated by Src and focal adhesion kinase. Sci. Rep. 5, 8453 (2015).","journal-title":"Sci. Rep."},{"key":"2229_CR24","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1152\/ajplung.00390.2011","volume":"303","author":"GQ Cai","year":"2012","unstructured":"Cai, G. Q. et al. Neuronal Wiskott-Aldrich syndrome protein (N-WASP) is critical for formation of \u03b1-smooth muscle actin filaments during myofibroblast differentiation. Am. J. Physiol. Lung Cell Mol. Physiol. 303, 692\u2013702 (2012).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"2229_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-04317-0","volume":"7","author":"XK Zhao","year":"2017","unstructured":"Zhao, X. K. et al. Focal adhesion kinase regulates hepatic stellate cell activation and liver fibrosis. Sci. Rep. 7, 4032 (2017).","journal-title":"Sci. Rep."},{"key":"2229_CR26","doi-asserted-by":"publisher","first-page":"26839","DOI":"10.1074\/jbc.M803645200","volume":"283","author":"Q Ding","year":"2008","unstructured":"Ding, Q., Gladson, C. L., Wu, H., Hayasaka, H. & Olman, M. A. Focal adhesion kinase (FAK)-related non-kinase inhibits myofibroblast differentiation through differential MAPK activation in a FAK-dependent manner. J. Biol. Chem. 283, 26839\u201326849 (2008).","journal-title":"J. Biol. Chem."},{"key":"2229_CR27","doi-asserted-by":"publisher","first-page":"12384","DOI":"10.1074\/jbc.M208544200","volume":"278","author":"VJ Thannickal","year":"2003","unstructured":"Thannickal, V. J. et al. Myofibroblast differentiation by transforming growth factor-beta1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase. J. Biol. Chem. 278, 12384\u201312389 (2003).","journal-title":"J. Biol. Chem."},{"key":"2229_CR28","doi-asserted-by":"publisher","first-page":"9565","DOI":"10.1074\/jbc.M310739200","volume":"279","author":"X Wu","year":"2004","unstructured":"Wu, X., Suetsugu, S., Cooper, L. A., Takenawa, T. & Guan, J. L. Focal adhesion kinase regulation of N-WASP subcellular localization and function. J. Biol. Chem. 279, 9565\u20139576 (2004).","journal-title":"J. Biol. Chem."},{"key":"2229_CR29","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3109\/10409230903277340","volume":"44","author":"R Dominguez","year":"2009","unstructured":"Dominguez, R. Actin filament nucleation and elongation factors-structure-function relationships. Crit. Rev. Biochem. Mol. Biol. 44, 351\u2013366 (2009).","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"issue":"(Pt 7)","key":"2229_CR30","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1242\/jcs.134692","volume":"127","author":"X Zhang","year":"2014","unstructured":"Zhang, X., Moore, S. W., Iskratsch, T. & Sheetz, M. P. N-WASP-directed actin polymerization activates Cas phosphorylation and lamellipodium spreading. J. Cell Sci. 127 (Pt 7), 1394\u20131405 (2014).","journal-title":"J. Cell Sci."},{"key":"2229_CR31","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nrm2069","volume":"8","author":"T Takenawa","year":"2007","unstructured":"Takenawa, T. & Suetsugu, S. The WASP-WAVE protein network: connecting the membrane to the cytoskeleton. Nat. Rev. Mol. Cell Biol. 8, 37\u201348 (2007).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2229_CR32","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.molonc.2009.01.002","volume":"3","author":"TP Green","year":"2009","unstructured":"Green, T. P. et al. Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Mol. Oncol. 3, 248\u2013261 (2009).","journal-title":"Mol. Oncol."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-2229-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-2229-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-2229-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T09:44:56Z","timestamp":1670233496000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-2229-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,12]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2]]}},"alternative-id":["2229"],"URL":"https:\/\/doi.org\/10.1038\/s41419-020-2229-2","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,12]]},"assertion":[{"value":"14 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"118"}}